Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
Summary
Absci priced an underwritten offering of 13,495,277 shares at $7.41 per share and expects to raise about $100 million gross. The company plans to use the proceeds to advance ABS-201 in androgenetic alopecia and endometriosis, and to support working capital and general corporate needs. Eli Lilly and several financial investors participated in the financing. The offering is expected to close on or about June 25, 2026, subject to customary conditions.
Funding
Amount
$100.0M
Total raised
Date
June 24, 2026
Announcement date
Investors
Jefferies, Eli Lilly and, Redmile Group, Guggenheim Partners, Adage Capital Management
Lead investors
Company
absci.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected